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Abstract Effectiveness of antiretroviral pre-exposure
prophylaxis (PrEP) for HIV prevention will require high
adherence. Using qualitative data, this paper identifies
potential lay social resources for support of PrEP adher-
ence by HIV serodiscordant couples in Uganda, laying the
groundwork for incorporation of these resources into
adherence support initiatives as part of implementation.
The qualitative analysis characterizes support for PrEP
adherence provided by HIV-infected spouses, children,
extended family members, and the larger community.
Results suggest social resources for support of PrEP
adherence in Africa are plentiful outside formal health care
settings and health systems and that couples will readily
use them. The same shortage of health professionals that
impeded scale-up of antiretroviral treatment for HIV/AIDS
in Africa promises to challenge delivery of PrEP. Building
on the treatment scale-up experience, implementers can
address this challenge by examining the value of lay social
resources for adherence support in developing strategies for
delivery of PrEP.
Resumen La efectividad de la profilaxis de pre-exposi-
cio´n (PrPE) para la prevencio´n de VIH requerira´ alta ad-
herencia. Utilizando informacio´n cualitativa, este articulo
identifica potenciales recursos en la sociedad civil para
apoyar la adherencia a PrPE por parejas serodiscordantes
en Uganda, estableciendo las bases para incorporar estos
recursos en las iniciativas de apoyo de adherencia como
parte de la implementacio´n. El ana´lisis cualitativo carac-
teriza el apoyo para adherencia a PrPE proporcionado por
parejas infectadas por VIH, nin˜os, otros miembros de la
familia y la comunidad en general. Los resultados sugieren
que los recursos sociales de apoyo para adherencia a PrPE
en A´frica son abundantes fuera de las los establecimientos
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de salud formales y del sistema de salud y que las parejas
los utilizarı´an fa´cilmente. La misma escasez de profesio-
nales de salud que impidio´ la implementacio´n a gran escala
del tratamiento anti-retroviral para VIH/SIDA en A´frica
promete desafiar la entrega de PrPE. Construyendo sobre la
experiencia de la implementacio´n a gran escala del tra-
tamiento, implementadores pueden abordar este desafı´o
examinando el valor de los recursos de la sociedad civil
para apoyar la adherencia en el desarrollo de estrategias
para la entrega de PrPE.
Keywords HIV Prevention  PrEP  Adherence 
Serodiscordant Couples  Sub-Saharan Africa  HIV Health
Care Delivery in Africa
Introduction
Plans and preparations for implementing HIV prevention
strategies using antiretrovirals (ARVs) are being debated
internationally. Evidence of efficacy of oral tenofovir
disoproxil fumarate (TDF) and coformulated emtricitabine/
tenofovir disoproxil fumarate (FTC/TDF) as pre-exposure
prophylaxis (PrEP) has been demonstrated for HIV-unin-
fected individuals [1–4] and approved by the US Food and
Drug Administration [5]. Mathematical modeling studies
examining PrEP impact in different populations highlight
the importance of risk level and adherence in determining
cost effectiveness [6–11]. Guidance on implementation
approaches is emerging [12, 13]. A number of demon-
stration projects evaluating delivery of PrEP are underway
in the US [14–20], and several more are taking place and/or
being planned in sub-Saharan Africa [21–23].
HIV serodiscordant couples represent the priority popula-
tion for implementation of ARV-based HIV prevention in
Africa. Half of HIV-infected persons in marital or cohabiting
relationships have partners who are not infected [24–26].
Rates of HIV transmission in serodiscordant couples are high,
ranging from 2 % to almost 12 % [27–30]. Serodiscordant
couples can be targeted for prevention efforts through pro-
motion of couples HIV counseling and testing [31].
International scale-up of antiretroviral therapy (ART)
for treatment of HIV-infection is considered a resounding
public health success [32–36]. The success of the scale-up
initiative has been achieved despite significant implemen-
tation challenges, prominent among them being shortages
of personnel qualified to deliver ART and provide clinical
follow-up care [37]. The human resources challenge has
been addressed in part through steadily increasing
involvement of laypersons in activities of care. Integrating
ARVs for prevention into HIV-related health services in
Africa will place additional responsibility on already
overburdened health systems.
Effectiveness of PrEP depends largely on adherence, as
indicated by the association between drug levels as an
objective adherence measure and efficacy in the four PrEP
trials in which efficacy has been demonstrated [1–4, 38–
45]. Adherence to ARVs for HIV treatment in Africa has
proven excellent [46–52], despite major structural barriers
to accessing and persisting in care [53–59]. Adherence to
ARVs for HIV prevention and the impact of potential
adherence barriers outside of clinical trials are not yet well
understood.
Excellent adherence to ARVs as HIV treatment in
Africa reflects a number of contributing factors. Great
emphasis has been placed on adherence as part of routine
clinical follow-up care. Many clinics have professional
staff (e.g., nurses, counselors) dedicated solely to providing
adherence education and support. Clinics have also drawn
liberally upon non-professional, community-based resour-
ces to support patients’ ART adherence efforts. For
example, having a treatment partner is a condition of
starting ART in many treatment programs. Treatment
partners are laypersons who are charged with helping HIV-
infected persons on ART adhere to daily dosing. A number
of experimental studies have now documented the impact
of treatment partners on ART adherence rates [60–62] and
clinical outcomes [63].
‘‘Peers’’ (‘‘persons living with HIV/AIDS’’) are also
increasingly being recognized in Africa as a non-profes-
sional resource with important contributions to make to
adherence. The roles of peers have steadily expanded from
education and support to include activities of care. As ART
scale-up took hold, peers were relied upon first to provide
emotional support and ‘‘positive role modeling’’—helping
patients to accept an HIV diagnosis and ‘‘live well’’ with
HIV/AIDS [63–65]. Over time, increases in the numbers of
persons receiving ART and acceptance of task-shifting [66]
have led to involvement of peers in ART drug resupply,
adherence monitoring, and routine clinical follow-up [67–
72]. Peer relationships and networks also perform a social
integration function, helping to de-stigmatize HIV/AIDS
and re-establish the standing of infected individuals in local
communities [67, 73].
Whether excellent ARV adherence will be achieved in
the prevention context—where the perceived need for
‘‘medicine’’ may be less urgent and the concept of ‘‘drugs
for prevention’’ less familiar—is an important and very real
question. The importance of adherence underscores the
need to understand how individuals will cope with taking
ARVs to prevent HIV infection, and how their efforts to
adhere can best be supported.
The adherence successes of ART scale-up in Africa
contain important lessons for replicating these successes as
ARVs become available for use in prevention. One such
lesson is that family members, friends and peers of persons
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taking ARVs are both interested in and capable of effective
adherence support for HIV treatment. Understanding this, it
makes sense to ask whether similar resources may be
available in the prevention context. We begin to address
this question by characterizing social influences on adher-
ence observed in the Partners PrEP Study, a randomized
clinical trial of daily oral PrEP for HIV prevention among
HIV serodiscordant couples in East Africa.
Methods
Ethical Approval
This study was approved by the Partners Health Care
Human Research Committee, Boston, MA; the Human
Subjects Division of the University of Washington, Seattle,
WA; and the Uganda Council on Science and Technology,
Kampala, Uganda. Written consent was obtained from all
participants.
Study Sample
This analysis is based on data collected through in-depth
qualitative interviews with 88 adults who were HIV-unin-
fected partners in Ugandan HIV-serodiscordant couples.
Qualitative interviewees were part of an ancillary adherence
substudy [44] that used validated objective measures [the
electronic medication event monitoring system (MEMS),
and unannounced home-based pill counts (UPCs)] to assess
adherence to study product in 1,147 participants in the
Partners PrEP Study from November 2009 through
December 2012. The Partners PrEP Study was a multi-site,
double-blind, randomized, placebo-controlled phase-III trial
evaluating the safety and efficacy of daily oral TDF and
FTC/TDF as PrEP to prevent HIV acquisition (ClinicalTri-
als.gov NCT00557245) [1]. In the adherence substudy,
adherence assessment data were collected at three Partners
PrEP Study sites (Kabwohe, Kampala, Tororo) in urban and
rural Uganda. MEMS recorded daily adherence. Unan-
nounced pill counts were conducted monthly for the first
6 months of study participation and quarterly thereafter.
Qualitative data were collected at the adherence substudy
site in Kabwohe, in rural southwest Uganda (See Fig. 1).
Sampling Strategy
A purposeful sampling strategy was used to identify
qualitative study participants. Purposeful sampling lays the
groundwork for in-depth qualitative analysis by systemat-
ically representing a variety of perspectives on an object of
study [74]. ‘‘Low’’ and ‘‘perfect’’ adherers to Partners PrEP
Study product (TDF, FTC/TDF as PrEP, or placebo) were
purposefully sampled to form participant groups with
contrasting adherence experiences. Low and perfect
adherence estimates were based on data from monthly or
quarterly UPCs carried out as part of the adherence sub-
study. Low adherers were individuals whose UPC adher-
ence dropped to 80 % or below. Perfect adherers were
individuals with UPC adherence rates of 100 %. Under-
standing low adherence was a priority; thus all adherence
substudy participants with a UPC adherence rate of \/
=80% were included in the qualitative study. Perfect adh-
erers were selected from adherence substudy participants
with 100 % adherence. Fifty-eight low adherers and 30
perfect adherers were included from a total of 367 ancillary
adherence substudy participants at the Kabwohe site.
Recruitment
Recruitment for the qualitative study took place over
27 months, from April 2010 to July 2012. Efficacy of PrEP
for HIV prevention was demonstrated and the Partners
PrEP Study unblinded in July, 2011, meaning that partic-
ipants entering the qualitative study after that time had
been informed they were receiving PrEP (rather than pla-
cebo) and that PrEP was efficacious [1]. Approximately
half (47 %, N = 41) of study interviews took place after
unblinding. Individuals identified as potential participants
were approached during routine Partners PrEP Study
clinical follow-up visits. They received an explanation of
the research and an invitation to participate. All of the 88
individuals who were invited agreed to take part. Following
recruitment, low adherers were offered an adherence sup-
port intervention as part of the adherence substudy [75].
The intervention took place after qualitative data collection
was complete.
Fig. 1 Qualitative research in relation to the ancillary adherence
substudy and Partners PrEP Study
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Data Collection
Qualitative interviews were carried out by Ugandan
research assistants (RAs) trained in qualitative research
methodology. They took place in private locations—in
patients’ homes, at the research offices, or near the clinic—
where conversations could not be overheard. Conversations
were audio-recorded with permission and typically lasted
about an hour. A qualitative interview guide was used to
address the following topics with each participant: (1)
experiences of taking study pills, (2) descriptions and
explanations of particular missed doses, (3) accounts of
adherence lapses (when more than a single dose was mis-
sed), (4) strategies for sustaining adherence, and (5) impact
of serodiscordance on the partnered relationship. Neutral
probes were used to elaborate responses and elicit illus-
trative examples. Following each interview, RAs generated
a complete transcript in English from local language audio
recordings. Transcripts were reviewed for quality (detail,
grammar, and style). The transcripts constitute the quali-
tative data analyzed for this report.
Data Analysis
The starting point for this qualitative analysis was the
explanation of PrEP adherence arrived at through our ini-
tial examination of these data, in which we identified the
desire to preserve the partnered relationship as an impor-
tant social motive for adherence to study product or pla-
cebo by HIV-uninfected individuals in the Partners PrEP
Study [76]. Our goal was to build upon these initial find-
ings through a broader examination of social resources for
supporting PrEP adherence in the HIV prevention context.
We therefore used an iterative process to re-analyze the
data for evidence of other types of social influences that
appeared to impact adherence.
The first and second authors reviewed the data for
content illuminating the roles or potential roles of layper-
sons in PrEP adherence [77]. The relevance and meaning of
the content was discussed. On the basis of the discussion,
relevant content was organized to form the descriptive
categories presented here. The categories were then illus-
trated using excerpts from the data.
In addition to the qualitative analysis, we compiled
descriptive quantitative data on personal characteristics of
the 88 qualitative participants and summarized rates of
adherence.
Results
Results of analyses are presented in the following order.
Quantitative data reporting personal characteristics and
adherence rates of the sample appear first, as background.
These are followed by categories describing lay social
resources for adherence support, the primary focus of this
analysis.
Personal Characteristics of Qualitative Study
Participants
Forty-eight men (54.5 %) and 40 women (45.5 %) made up
the qualitative study sample. Median age for the group was
34.5 years (IQR 29.8–39.3 years). All participants descri-
bed themselves as married and living with their partners at
the time of enrollment. ‘‘Marriage,’’ as the term is used
locally, refers to unions that may or may not have been
sanctioned by a religious or civil authority. Median dura-
tion of the partnered relationship was 7.6 years (IQR
4.1–16.2 years). Most (84.1 %) participants had children
with their partners; median number of children was 2.
Median adherence was 90 % (IQR 83.7–95.5 %) for low
adherers and 100 % (IQR 99.6–100.3 %) for perfect adh-
erers by UPC for the duration of their participation in the
ancillary adherence substudy.
Qualitative Results: Lay Social Resources for Support
of PrEP Adherence
Qualitative analysis identified a number of potential lay
social resources for support of PrEP adherence. These are
detailed below under the headings: (1) The partnered
relationship as adherence support, (2) Adherence as a
‘‘Family Affair,’’ and (3) Relationship support as adher-
ence support for serodiscordant couples.
The Partnered Relationship as Adherence Support
Relationship partners provided direct adherence support for
HIV-uninfected individuals taking study product or placebo.
Support ranged from simple encouragement to ‘‘keep taking
your pills,’’ to presenting pills and accompanying water and/
or food for easy dosing at the scheduled time, to running
after a departing spouse with a forgotten pill bottle in hand.
Often, support involved sharing adherence responsibility by
offering reminders at dosing times. Couples in which the
HIV-infected partner was also taking ART or cotrimoxazole
as prophylaxis often took their pills together. The following
examples from interview transcripts illustrate the ways in
which partners provided adherence support:
Interviewer: ‘‘How does your partner assist you in
swallowing your medicine?’’
Respondent: ‘‘Well, there are times when she reminds
me. We can be there conversing and then she checks on
814 AIDS Behav (2015) 19:811–820
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the clock and tells me that it’s time for medicine. Then,
she brings it to me and I swallow.’’
Male, Low Adherer, Age 19
Interviewer: ‘‘How did you then decide to resume taking
the drugs?’’
Respondent: ‘‘When I came back home, I started again
taking my drugs. This was after asking my husband what
I should do, because I had feared the drugs. He tried to
explain to me because for him he understood better what
we had been told at the clinic. He assured me that the
drugs had no problem and encouraged me to resume and
I did so.’’
Female, Low Adherer, Age 29
He [husband] really helps me a lot. ….He tries to
remind me and he keeps encouraging me to swallow
my medicine well. He tells me never to miss even for
a day. If he suspects I don’t have money for transport
[to clinical follow-up visits] he will meet me on the
way [to the clinic] and give it to me. I have never
lacked transport, not even for a single day. If he
doesn’t have money, he will borrow from friends at
work and bring it to me.
Female, Perfect Adherer, Age 27
Interviewer: ‘‘How does your partner help you in
swallowing your drugs?’’
Respondent: ‘‘She helps me a lot and I also help her a lot
because every night she is also swallowing her drugs.’’
Interviewer: ‘‘How does she help you?’’
Respondent: ‘‘The way she helps me [is], we agreed on
the time when we should be having supper, and we also
agreed that by the time everyone swallows their drugs,
they should have eaten supper first. So for us by 8.20
p.m. we are always through with supper. After supper,
we reach for our drugs and swallow them.’’
Male, Perfect Adherer, Age 44
Adherence as Family Affair
Partners were not the only family members provid-
ing adherence support. Children were also actively
involved. Interviewee reports consistently depicted chil-
dren as eager to contribute and conscientious in reminding
their parents to take their pills at dosing times. Even young
children proved themselves to be reliable ‘‘reminders’’:
Interviewer: ‘‘How do you remember to take your pills?’’
Respondent: ‘‘I told my child. When it clocks 7:00 p.m.,
he comes and tells me to swallow my medicine.’’
Interviewer: ‘‘How old is he?’’
Respondent: ‘‘He is six years.’’
Interviewer: ‘‘How does he tell the time?’’
Respondent: ‘‘I told him that I am supposed to swallow
this medicine at 7:00 p.m., so he should remind me in
case I forget. We don’t have a watch but he is able to
somehow tell that it’s time. I have a radio, but I never
have time for it. I don’t have a phone. It’s my son who
reminds me.’’
Female, Perfect Adherer, Age 34
Interviewer: ‘‘Besides the phone and the radio; what else
reminds you to swallow your medicine?’’
Respondent: ‘‘My children. When it’s time, they tell me
‘Mum, its time.’’’
Interviewer: ‘‘How did your children know that you
swallow medicine?’’
Respondent: ‘‘I explained to them. I told those who are
older; I told them the truth and showed them the pills.
That time, I had not yet bought a phone; so, they would
remind me always. They have a name for my medicine;
they call it ‘ground nuts [a peanut common in the
region].’ So, they always say that, ‘Mum, it’s time to
swallow your ground nuts.’ Even if the radio is off and
maybe my phone has no battery, they will come and ask
‘Mum, don’t you think it’s time for your ground nuts?’’’
Female, Perfect Adherer, Age 42
Children typically become involved in adherence when
asked to do so by a parent, as in the examples above. Help
can also be requested from other family members to create
a family network of adherence support. Creating a family
adherence support network presupposes disclosure of HIV-
positive status but changes its meaning. Rather than a
threat, disclosure for activation of family support becomes
a means to a desired end. Making adherence into ‘‘a family
affair’’ through disclosure is a culturally congruent adher-
ence strategy that makes effective use of available social
resources. One woman described how she accomplished
this:
It’s not common to forget [a dose], because when I
got this medicine, I reached home and showed it to
everyone, including the children, and told them the
time I am supposed to swallow it. Even when I am at
my mother-in-law’s place, you find her asking me
AIDS Behav (2015) 19:811–820 815
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whether I remembered to swallow the medicine. Even
the children remind me. And when my husband is
around, he also reminds me. This is what has helped
me swallow my medicine well. Because when you
keep it a secret and you hide it from other people, you
will forget and there won’t be anybody to remind
you. It’s important that other people are in the know
so they can remind you.
Female, Low Adherer, Age 30
Relationship Support as Adherence Support
for Serodiscordant Couples
Authors of a recent ethnographic analysis explaining why
marriage and childbearing, as life priorities, may interfere
with HIV treatment in a West African society characterized
marital relationships as ‘‘collective projects in which families
and communities are highly invested’’ [78]. In daily life, this
means in-laws, friends, andneighborsmaybe expected to play
an active role in supportingmarried couples and keeping their
unions intact. Evidence of this was apparent in our qualitative
data, which contained stories of one or another spouse seeking
refuge in a neighbor’s home to ‘‘cool off’’ following an
argument, and accounts of family interventions aimed at
reconciling couples living separately due to discord in the
relationship. The following examples illustrate:
When [I saw] that he [husband]was infectedwithHIV, I
spent several months without having sex with him. I
packed my bags and went to my parents’ home. I spent
three months there. Then some elderly man in my hus-
band’s neighborhood came and pickedme to go back to
him. I accepted. But when I reached there, he again
wanted me to have sex with him. I refused totally and
packedmybags again andwent back tomyparents. This
time his brothers onhis paternal uncle’s side came. They
asked him the reason why we were separating. Then
they concluded that since I was the only known wife, I
should be left to be at home and raise my children but he
gives me my peace. That is when I again went back to
him. They asked him whether he agreed with the deci-
sion and he accepted. So I went back.
Female, Low Adherer, Age 39
I was going through his things and found some medi-
cine and hismedical forms. I asked him to explain what
they were. He instead quarreled, asking why I went
through his things without his knowledge. I decided to
go home tomyparents. He didn’t wantme to leave but I
insisted. [Later] he followed me to my home. My
parents were present. I told them the reason I left was
because I foundmy husbandwith pills in his bag and he
told me he is HIV-positive. I told them I didn’t want to
go back to his home. My parents gave us advice. They
said, ‘haven’t you seen people who are positive and are
living together?’ They told us to go to the hospital and
seek guidance from health workers. Since the time we
joined the study, we have not quarreled at all.
Female, Perfect Adherer, Age 27
In addition to family, friends and neighbors, the inter-
views point to other existing resources in local communi-
ties available for relationship support. These include a
range of formal organizations (e.g. churches, NGOs), as
well as individuals seen as community leaders (e.g., elders,
tribal heads). Couples do not hesitate to draw on these
resources in working to resolve threats to their relationship.
After some time, I told him, ‘if you do not want to test
with me, remain alone and I also will remain alone.’We
separated. Good enough. The person who tested me is
my friend, and he started advising me.…He insisted if
we both went to him, he would teach us how to use a
condom. Thenmy husband said, ‘I cannot use a condom
onmywife.’ I toldhim I cannot accept unprotected sex. I
said, ‘if this is [how it is], let us remain separate.’ So we
separated our beds. Then, because we are legally mar-
ried, hewent and reportedme to church leaders. They sat
us down and talked to us about our issues. Laterwewent
to [health center in a nearby town]. They also educated
him.They toldhim if hedoesnot accept, he should allow
me to go back to my parents’ home. That is when he
accepted and started using condoms. From that time we
reconciled and became one.
Female, Perfect Adherer, Age 48
Respondent: ‘‘He [husband] has said that the very few
times I agree to have sex with him do not satisfy him.
But if he was using condoms very well, I wouldn’t be
having any problem. When we have sex [infrequently],
they have not broken. But when the frequency of sex
increases, the condoms break. …Sometimes we spend a
week apart because he has chased me from home [over
this]. I spend nights at different people’s homes.’’
Interviewer: ‘‘How helpful have these people been in
resolving your disagreements?’’
Respondent: ‘‘They try to arbitrate but we disagree
afresh. Actually, there is no place we haven’t been to [to
seek help]. We started by going to the counselors at
TASO [The AIDS Service Organization, Ugandan
NGO]. We went to the probation office at the district.
We went to the police. It is only the family members
who have not met. This is the remaining option.’’
816 AIDS Behav (2015) 19:811–820
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Female, Low Adherer, Age 29
Interviewer: ‘‘How did your discordant status affect how
you get along with your husband in the relationship?
Respondent: ‘‘He first wanted to always sleep with me
without a condom. We feuded over this and I ended up
separating from him andwent back tomy parents for some
time. He followed me home and I disclosed to my parents
what the issue was. They called a meeting of counselors
and elders in the village, who gave him advice. He heeded
their advice, andwe agreed to use condom, which I always
get from the health center, nearby.’’
Female, Perfect Adherer, Age 36
Our qualitative data point to relationship partners as
direct sources of adherence support to HIV-uninfected
individuals taking PrEP or placebo as part of this study. If
partners provide direct support, then efforts to help sero-
discordant couples repair their relationships and live
together without discord represent indirect resources for
support of adherence already existing in communities.
Discussion
Good adherence will be central to success in using ARVs
to prevent HIV transmission and curb the epidemic.
Adherence is enhanced through consistent adherence sup-
port. In Africa, professional resources for providing such
support may be scarce, but informal, lay resources are
likely to be both plentiful and effective. Through qualita-
tive data, this paper offers a glimpse of what family and
community-based support for PrEP adherence from spou-
ses, other family members, and the larger community
might look like for African serodiscordant couples who
choose to disclose their serodiscordant status.
This paper documents the availability of social resources
to support couples in adherence to ARV-based prevention.
The next step will be to develop strategies and systems for
deploying these resources. At least two general approaches
present themselves to start. Ways of integrating laypersons
into activities of clinical care—working alongside profes-
sionals in clinics as educators or counselors—need to be
identified. At the same time, these resources can serve as
building blocks for the construction of a community-based
network that might support adherence, facilitate disclosure,
combat stigma, help couples negotiate relationship prob-
lems, and educate the public about the use of ARVs for
prevention. Existing community-based support organiza-
tions in which HIV-affected families are already active or
have a stake might provide good starting points. Examples
include church-sponsored couples’ education and support
groups, civic groups active in supporting HIV-prevention
activities (e.g. testing), and/or groups organized for eco-
nomic self-help.
ART is a lifetime commitment, but use of PrEP by
African serodiscordant couples will likely be time-limited.
In East and West African Demonstration Projects, couples
are being offered PrEP as a ‘‘bridge’’ to initiation of ART
[22, 79]. In the ‘‘bridging strategy’’ of PrEP delivery, HIV-
uninfected partners in serodiscordant couples are offered
PrEP until the infected partner begins ART and is virally
suppressed, at which point PrEP is discontinued. It may
also be that couples will rely on PrEP when other forms of
protection are not feasible (as when trying to conceive) or
available. The time-limited nature of PrEP use means the
need for adherence support from lay social resources will
also be time-limited.
Adherence to PrEP may be more variable and more
challenging than adherence to antiretroviral treatment, as
the motivating effect of dramatic health gains after starting
ART will be lacking. Data on PrEP adherence in demon-
stration projects are just beginning to appear. An early
report on adherence to daily oral PrEP by HIV-uninfected
partners in serodiscordant couples taking part in the Part-
ners Demonstration Project in Kenya and Uganda shows
both high adherence and frequent (unintentional) gaps and
(intentional) breaks [80]. Understanding the reasons behind
gaps and breaks, the associated risk of HIV exposure, and
adherence levels will be central to research on PrEP
adherence, given the likely variability in the ways it will be
used.
Purposeful sampling intentionally represents varying
perspectives on a topic of study through the inclusion of
participant groups with contrasting experiences. In this
sample, varying perspectives are represented through
inclusion of low and perfect adherers. The sample was not
constructed to identify differences among constituent sub-
groups; thus our analysis of group differences is limited.
Qualitatively, we determined generally that identified cat-
egories of adherence support applied to both low and
perfect adherers. Illustrative examples from both groups are
included in the descriptions of each category as confirma-
tion of this.
We have argued here for the importance of partners as
sources of adherence support. Accordingly, discord in the
relationship can detract from adherence success. A partner
leaving home in anger after an argument may forget to take
pills along. Tension and fighting with a spouse can
undermine adherence motivation when typically the very
reason for accepting ARVs is to preserve the relationship.
Adherence support provided by a partner and/or by being
in a partnered relationship is likely enhanced when the
relationship is stable.
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The following limitations of this analysis should be
pointed out. The data were collected in a research setting in
which adherence was both investigated and consistently
reinforced. This may have resulted in greater involvement in
adherence by family members and friends than might be
typical outside the context of research. At the same time, the
qualitative study was not designed and did not set out to
elicit data on lay social resources for adherence support. The
clear evidence of social involvement in adherence that
emerged from the interview data suggests both that the
phenomenon is real and that more could have been learned
about a broader array of sources of support in the commu-
nity, had this been a study focus. Nevertheless, the lack of
initial focus on lay social resources for adherence support
means some categories, notably the Relationship Support as
Adherence Support category, could not be fully developed.
Data for this qualitative study were collected at a single
site in one country only, limiting generalizability. Most
qualitative research, this study included, does not aim for
generalizability but rather at the delineation and interpre-
tation of concepts. Qualitatively, limiting data collection to
a single site in a single country means variation across
communities and/or cultural settings cannot be addressed.
Conclusion
Effectiveness of ARVs for prevention of HIV transmission
depends on adherence success. Support from professionals,
peers, family members and friends has been central to the
excellent adherence achieved by individuals in Africa
taking ART for HIV treatment.
ART scale-up has brought increasing involvement of
laypersons in activities of care as a means of alleviating
health care personnel shortages. Now, with evidence of the
efficacy of TDF and FTC/TDF as PrEP, pressures on
overburdened health systems will once again intensify. As
PrEP is implemented in demonstration projects and routine
health care settings, it is important to identify acceptable
and effective strategies to optimize adherence and reduce
burden on clinic staff. These qualitative data suggest lay-
persons—family members, peers, members of the larger
community—constitute a promising resource for PrEP
adherence support that merits further investigation.
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